Author: "Kristy M. Walsh" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Kristy M. Walsh"' showing total 220 results

Start Over Author "Kristy M. Walsh"

220 results on '"Kristy M. Walsh"'

1. Data from Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas

Author: Stephen J. Schuster, Kristy M. Walsh, Anthony R. Mato, Sunita D. Nasta, Jakub Svoboda, Nicole A. Aqui, Tahamtan Ahmadi, and Elise A. Chong
Abstract: Purpose: Lenalidomide, an immunomodulatory agent that enhances antibody-dependent cell-mediated cytotoxicity, has the potential to synergize with rituximab, an anti-CD20 mAb. We hypothesized that the addition of lenalidomide to rituximab would improve clinical outcomes in patients with B-cell lymphomas who were previously rituximab resistant, defined as no response to or progression of lymphoma within 6 months of rituximab-based therapy.Experimental Design: We conducted a single-center, phase II trial in patients with indolent B-cell or mantle cell lymphomas who were previously rituximab resistant. Patients received 10 mg lenalidomide daily for 8 weeks, and then received four weekly doses of 375 mg/m2 rituximab; lenalidomide continued during and after rituximab. Response to therapy was assessed after 8 weeks of lenalidomide and 12 weeks after first dose of rituximab. The primary endpoint was overall response rate (ORR) after lenalidomide and rituximab.Results: Fifty patients were enrolled and 43 patients completed both response assessments. ORR after 8 weeks of lenalidomide was 30.2%; 12 weeks after the addition of rituximab to lenalidomide, ORR increased to 62.8% (N = 43). For all patients (N = 50), median progression-free survival (PFS) is 22.2 months (median follow-up, 39.2 months). PFS after lenalidomide–rituximab was significantly longer than the PFS for the antecedent regimen used to define rituximab resistance (22.2 vs. 9.13 months, P = 0.0004).Conclusions: This trial is the first to show that the combination of lenalidomide and rituximab overcomes prior rituximab resistance in patients with indolent B-cell and mantle cell lymphomas. Clin Cancer Res; 21(8); 1835–42. ©2015 AACR.
Published: 2023

2. Lenalidomide plus rituximab in patients with rituximab-resistant indolent B-cell and mantle cell lymphomas: 10-year follow-up

Author: Ellen Napier, Kristy M. Walsh, Elise A. Chong, Sunita D. Nasta, Jakub Svoboda, Stephen J. Schuster, and Aditi Gupta
Subjects: Oncology, Cancer Research, medicine.medical_specialty, business.industry, 10 year follow up, Cell, medicine.anatomical_structure, Mantle (API), hemic and lymphatic diseases, Internal medicine, medicine, In patient, Rituximab, business, B cell, Lenalidomide, medicine.drug
Abstract: 7539 Background: Lenalidomide (len) plus rituximab is now a standard-of-care option for indolent B-cell non-Hodgkin lymphomas (iNHL) and mantle cell lymphomas (MCL). We previously demonstrated the efficacy of len plus rituximab in patients (pts) with rituximab-refractory iNHL and MCL (Chong et al. Clin Can Res 2015). We now report the longest experience to date with this regimen. Methods: We conducted an open-label phase II trial in pts with iNHL or MCL and rituximab resistance, defined as failure to respond or progression of disease within 6 months (mo) of rituximab or a rituximab-containing regimen. Pts received len 10 mg daily for 8 weeks, followed by 4 weekly doses of rituximab 375 mg/m2 and continued len maintenance until disease progression, toxicity or pt choice. Results: 50 pts (30 FL, 14 MCL, 2 MZL, 4 SLL) were treated between 2008-2012. Median follow-up was 10.5 years (yr). Pts received a median of 3 prior therapies (range: 1–7). Progression free survival (PFS) for all pts at 5 and 10 yrs was 20.0% [95%CI 8-35] & 13% [95%CI 3-30%]; 5- and 10-yr response duration (RD) was 27% [95% CI 12-46] and 18% [95% CI 4-40], respectively; 5- and 10-yr overall survival (OS) was 58% [95%CI 43-70] and 45% [95%CI 30-58], respectively. 5-yr OS from the time pts were deemed rituximab-resistant is 64.0% and 10-yr OS 51.9%. For pts with FL, 5- and 10-yr PFS were both 13%, and 5- and 10-yr OS were 60% and 40%. For MCL, 5- and 10-yr PFS were both 25% and 5- and 10-yr OS were 50% and 36%. At 10.5 yr, 4 pts (2 FL, 1 MCL, 1 MZL) remain in complete remission (CR), 3 of whom discontinued len at 7.0-yr, 8.8-yr and 10.1-yr in CR. 1 pt with FL discontinued study in CR after 11.6-yr but continues on commercial len at 5 mg daily. The most common grade 1–2 adverse events (AEs) requiring dose reductions were neuropathy (n = 3) and diarrhea (n = 5), which all resolved with dose reduction. The most common grade 3–4 AEs requiring dose reductions were neutropenia (n = 6, 12%) and tumor flare (n = 3, 6%). Pts discontinued therapy due to toxicity at a median of 4.9 mo (range 0.3–25.7) from len start due to grade 3–4 rash (n = 2), grade 2 abdominal pain (n = 1), and grade 3–4 thrombocytopenia (n = 2). Only 1 patient discontinued len after > 1 yr (25.7 mo) due to persistent diarrhea. The pt who developed grade 2 abdominal pain was retreated with len without recurrence of pain and sustained a second CR for 5 yrs. 5 (10%) pts developed secondary cancers at a median of 15.5 mo (range: 0.8–50.5) from starting len, including 2 hematological (acute myeloid leukemia, B-acute lymphoblastic leukemia) and 3 solid cancers (NSCLC, renal cell carcinoma, prostate cancer). Prior to enrollment, 4/5 of the patients with secondary cancers had received alkylating agents and 3/5 had received anthracyclines. Conclusions: These data represent the longest reported outcomes for len plus rituximab in NHLs. We demonstrate durable responses and a manageable safety profile with rituximab plus low-dose len. Clinical trial information: NCT00783367.
Published: 2021

3. Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas

Author: Nicole A. Aqui, Tahamtan Ahmadi, Stephen J. Schuster, Kristy M. Walsh, Sunita D. Nasta, Jakub Svoboda, Anthony R. Mato, and Elise A. Chong
Subjects: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Lymphoma, B-Cell, Genotype, Lymphoma, Mantle-Cell, Drug resistance, T-Lymphocytes, Regulatory, immune system diseases, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, Lenalidomide, Aged, Aged, 80 and over, business.industry, Receptors, IgG, Cancer, Middle Aged, medicine.disease, Thalidomide, Tumor Burden, Lymphoma, Clinical trial, Regimen, Treatment Outcome, Drug Resistance, Neoplasm, Retreatment, Immunology, Female, Rituximab, Neoplasm Grading, business, Follow-Up Studies, medicine.drug
Abstract: Purpose: Lenalidomide, an immunomodulatory agent that enhances antibody-dependent cell-mediated cytotoxicity, has the potential to synergize with rituximab, an anti-CD20 mAb. We hypothesized that the addition of lenalidomide to rituximab would improve clinical outcomes in patients with B-cell lymphomas who were previously rituximab resistant, defined as no response to or progression of lymphoma within 6 months of rituximab-based therapy. Experimental Design: We conducted a single-center, phase II trial in patients with indolent B-cell or mantle cell lymphomas who were previously rituximab resistant. Patients received 10 mg lenalidomide daily for 8 weeks, and then received four weekly doses of 375 mg/m2 rituximab; lenalidomide continued during and after rituximab. Response to therapy was assessed after 8 weeks of lenalidomide and 12 weeks after first dose of rituximab. The primary endpoint was overall response rate (ORR) after lenalidomide and rituximab. Results: Fifty patients were enrolled and 43 patients completed both response assessments. ORR after 8 weeks of lenalidomide was 30.2%; 12 weeks after the addition of rituximab to lenalidomide, ORR increased to 62.8% (N = 43). For all patients (N = 50), median progression-free survival (PFS) is 22.2 months (median follow-up, 39.2 months). PFS after lenalidomide–rituximab was significantly longer than the PFS for the antecedent regimen used to define rituximab resistance (22.2 vs. 9.13 months, P = 0.0004). Conclusions: This trial is the first to show that the combination of lenalidomide and rituximab overcomes prior rituximab resistance in patients with indolent B-cell and mantle cell lymphomas. Clin Cancer Res; 21(8); 1835–42. ©2015 AACR.
Published: 2015

4. Young patients with chest pain: 1-year outcomes

Author: Judd E. Hollander, Christine M. McCusker, Kristy M. Walsh, Benjamin Weisenthal, Frances S. Shofer, and Mark J. Collin
Subjects: Adult, Male, Chest Pain, medicine.medical_specialty, Time Factors, Myocardial Infarction, Chest pain, Electrocardiography, Young Adult, Risk Factors, Internal medicine, Intensive care, medicine, Humans, Prospective Studies, Myocardial infarction, Acute Coronary Syndrome, Prospective cohort study, business.industry, Age Factors, General Medicine, Emergency department, Prognosis, medicine.disease, Surgery, Cohort, Emergency Medicine, Female, Myocardial infarction diagnosis, medicine.symptom, Emergency Service, Hospital, business, Social Security Death Index
Abstract: Prior studies found that young adult chest pain patients without known cardiac disease with either no cardiac risk factors or a normal electrocardiogram (ECG) are at low risk (1%) for acute coronary syndromes (ACS) and 30-day cardiovascular events. Longer-term event rates in this subset of patients are unknown. We hypothesized that patients younger than 40 years without past cardiac history and a normal ECG are at less than 1% risk for 1-year adverse cardiovascular events.We conducted a prospective cohort study in an urban university emergency department evaluating patients younger than 40 years who received an ECG for evaluation of potential ACS. Cocaine users, cancer patients, and patients with a history of myocardial infarction or revascularization were excluded. Structured data collection at presentation included demographics, chest pain description, history, laboratory results, and ECG data. Hospital course was followed. Follow-up was obtained by telephone, record review, and social security death index search. Our main outcome was 1-year adverse cardiovascular events (death; acute myocardial infarction [AMI]; or revascularization-percutaneous coronary intervention [PCI] or coronary artery bypass graft). Descriptive statistics and 95% confidence intervals were used.Of 3846 chest pain patients, 609 met criteria. Of those, 35.5% were admitted. Patients had a mean age of 34.8 years (SD, 3.8 years). They were most often female (57.6%) and black (69.5%). There were 7 patients (1.1%; 95% CI, 0.5%-2.4%) with adverse cardiovascular events over the year. Of the subset of 560 patients with a normal/nonspecific ECG, there were 2 deaths (0.4%), 3 AMI (0.5%), and 2 PCIs (0.4%) by 1 year for a composite adverse cardiovascular event rate of 6 (1.1%; 95% CI, 0.4%-2.3%). Of the subset of 269 patients with no cardiac risk factors and a normal/nonspecific ECG, there were no deaths, 1 AMI, and 1 PCI for a composite adverse cardiovascular event rate at 1 year of 0.3% (0.01%-2.1%). The addition of an initial cardiac marker to this group resulted in a cohort that was event-free at 1 year (95% CI, 0%-1.4%).Patients younger than 40 years without a cardiac history who present to the ED with symptoms consistent with ACS but have either no risk factors or a normal or nonspecific ECG have a very low rate of adverse events during the subsequent year.
Published: 2011

5. Relationship Between Cocaine Use and Coronary Artery Disease in Patients With Symptoms Consistent With an Acute Coronary Syndrome

Author: Judd E. Hollander, Kristy M. Walsh, Anna Marie Chang, Christine M. McCusker, Frances S. Shofer, and Harold Litt
Subjects: Univariate analysis, medicine.medical_specialty, Acute coronary syndrome, business.industry, General Medicine, Emergency department, medicine.disease, Thrombosis, Coronary artery disease, Relative risk, Internal medicine, Emergency Medicine, Cardiology, Medicine, Myocardial infarction, business, TIMI
Abstract: ACADEMIC EMERGENCY MEDICINE 2011; 18:1–9 © 2011 by the Society for Academic Emergency Medicine Abstract Objectives: Observational studies of patients with cocaine-associated myocardial infarction have suggested more coronary disease than expected on the basis of patient age. The study objective was to determine whether cocaine use is associated with coronary disease in low- to intermediate-risk emergency department (ED) patients with potential acute coronary syndrome (ACS). Methods: The authors conducted a cross-sectional study of low- to intermediate-risk patients
Published: 2010

6. Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality

Author: Allison C. Rosenthal, Tong Shen, Wei He, Kristy M. Walsh, Heather Walker, Yuqin Song, Mitchell E. Hughes, Han Tun, Laura Leary, Stephen J. Schuster, Emily Leblond, Lijuan Deng, Wei Ding, David L. Porter, Daniel J. Landsburg, Jun Zhu, Sunita D. Nasta, Jakub Svoboda, Kaitlin Kennard, Barry Douglas Anderson, Elizabeth T Chatburn, Scott F. Huntington, Ellen Napier, Anthony R. Mato, Tanya Latorre, Danielle M. Brander, Colleen Dorsey, Victoria Addis, Kylie Boyhen, and Jennifer Gill
Subjects: medicine.medical_specialty, business.industry, Immunology, Fixed-dose combination, Cell Biology, Hematology, medicine.disease, Pomalidomide, Biochemistry, Lymphoma, Phase i study, Clinical trial, Kite Pharma, Maximum tolerated dose, Partial response, Family medicine, medicine, business, health care economics and organizations, medicine.drug
Abstract: Background: Synthetic lethality (SL) is characterized by the chemical inhibition of multiple aberrant genes to differentially kill malignant cells. We investigated small-molecule combinations for SL through in vitro and in vivo screening and optimization studies (as in the granted patents in USA and China) and demonstrated the synergistic potential of best-in-class combinations of targeted agents, drug repositioning, immune modulation and low-dose combinations. We hypothesize that BTK and mTOR inhibition coupled with an IMID will target multiple key signaling pathways, improve differential apoptosis and target acquired drug resistance. DTRM-555, an optimized mechanism-based combination, consists of the clinically differentiated BTK inhibitor DTRMWXHS-12 (or DTRM-12), everolimus (EV) and pomalidomide (POM). In xenograft tumor models, DTRM-555 administered orally has demonstrated superior efficacy over monotherapy at very low dose combinations of the three agents (1/18 of DTRM-12, 1/6 of EV, and 1/6 of POM). DTRM-12 monotherapy has been safe and well tolerated in simultaneous phase Ia trials (US and China) with preliminary efficacy across 50 mg through 400 mg once daily (QD). Here we report the US clinical results of the oral combination therapies DTRM-505 (DTRM-12 plus EV) and DTRM-555 (DTRM-12 plus EV plus POM) for the first time (NCT02900716). Methods: The safety and anti-tumor activity of the oral doublet therapy DTRM-505 and the oral triplet therapy DTRM-555 are evaluated using a "3+3" study design. Enrollment was conducted concurrently with a phase Ia study of DTRM-12 monotherapy; with DTRM-505 opened for accrual when monotherapy DTRM-12 cleared the 200-mg dose level. Eligible patients are at least 18 years old, having ECOG performance status less than 2 with relapsed/refractory chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL) or classical Hodgkin lymphoma (cHL). Study treatment is administered daily for 21 consecutive days over a 28-day cycle. The dose-limiting toxicity (DLT) period was defined during the first cycle of therapy, and treatment was continued until disease progression or unacceptable toxicity. Patients underwent tumor evaluations every 2 months and response was recorded using revised response criteria (IWCLL and Cheson 2014). Results: Between 9/2016 and 7/2018, 19 patients have been treated with DTRM-12 monotherapy in the USA (6 pts, 50-300 mg) and China (13 pts, 50-400 mg). Patients have tolerated up to 23+ cycles of DTRM-12 monotherapy. Seven patients, including DLBCL, CLL, MCL, FL and cHL, have been treated with oral doublet therapy DTRM-505 for 2 to 12 cycles. Three patients (2 DLBCL, 1 FL) have been treated with oral triplet therapy DTRM-555, including one patient transitioned from the doublet DTRM-505 under an exploratory arm. No patient has discontinued due to an adverse event (AE) and no DLT has occurred. Recurring AEs are mostly grade 1 or 2 and responses have been seen with DTRM-505 and DTRM-555 across diverse lymphoma histologies (See Tables). All patients evaluable for response demonstrated partial response to DTRM-505 and DTRM-555, with 2/7 (doublet) and 3/3 (triplet) patients remaining on therapy. Conclusion: The maximum tolerated dose has not been reached for DTRM-12 monotherapy and for the current fixed dose doublet and triplet combinations. Toxicities have been mild and repeated cycles of study treatment have been well tolerated without delays of subsequent treatment cycles. Enrollment continues for refractory lymphoma patients to demonstrate the safety and efficacy for the first-in-class oral triplet therapy DTRM-555. Disclosures Huntington: Janssen: Consultancy; Bayer: Consultancy; Celgene: Consultancy. Schuster:Merck: Consultancy, Honoraria, Research Funding; Genentech: Honoraria, Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees; OncLive: Honoraria; Dava Oncology: Consultancy, Honoraria; Physician's Education Source, LLC: Honoraria; Nordic Nanovector: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis Pharmaceuticals Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Membership on an entity's Board of Directors or advisory committees. He:Zhejiang DTRM Biopharma Co. Ltd.: Other: Founder and CEO; Zhejiang DTRM Biopharma LLC: Other: Founder and CEO. Shen:Zhejiang DTRM Biopharma LLC: Other: Clinical Operations Director. Kennard:AbbVie, Gilead, Verastem: Consultancy. Dwivedy Nasta:Incyte: Research Funding; Takeda/Millenium: Research Funding; Debiopharm: Research Funding; Pharmacyclics: Research Funding; Rafael/WF: Research Funding; Aileron: Research Funding; Roche: Research Funding; Merck: Other: DSMC; Celgene: Membership on an entity's Board of Directors or advisory committees. Landsburg:Takeda: Consultancy; Curis: Consultancy, Research Funding. Porter:Novartis: Other: Advisory board, Patents & Royalties, Research Funding; Genentech: Other: Spouse employment; Kite Pharma: Other: Advisory board. Svoboda:Bristol-Myers Squibb: Consultancy, Research Funding; TG Therapeutics: Research Funding; Kyowa: Consultancy; Regeneron: Research Funding; Merck: Research Funding; Seattle Genetics: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; KITE: Consultancy. Song:Peking University Cancer Hospital (Beijing Cancer Hospital): Employment. Zhu:Beijing Cancer Hospital: Employment. Brander:Pharmacyclics, an AbbVie Company: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Other: Institutional research funding for non investigator initiated clinical trial, Research Funding; TG Therapeutics: Consultancy, Honoraria, Other: Institutional research funding for non investigator initiated clinical trial, Research Funding; Novartis: Consultancy, Other: DSMB; Genentech: Consultancy, Honoraria, Other: Institutional research funding for non investigator initiated clinical trial, Research Funding; Teva: Consultancy, Honoraria; Acerta: Other: Institutional research funding for non investigator initiated clinical trial, Research Funding; DTRM: Other: Institutional research funding for non investigator initiated clinical trial, Research Funding; BeiGene: Other: Institutional research funding for non investigator initiated clinical trial, Research Funding. Ding:Merck: Research Funding. Mato:Pharmacyclics, an AbbVie Company: Consultancy, Research Funding; AstraZeneca: Consultancy; Regeneron: Research Funding; Celgene: Consultancy; Acerta: Research Funding; TG Therapeutics: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; Portola: Research Funding; Johnson & Johnson: Consultancy; Prime Oncology: Honoraria; Medscape: Honoraria.
Published: 2018

7. Clinical Outcomes of Venetoclax Therapy in Patients with Relapsed/Refractory (r/r) Non Hodgkin Lymphomas (NHL)

Author: Sunita D. Nasta, Jakub Svoboda, Stephen J. Schuster, Danielle Land, Kristy M. Walsh, Colleen Timlin, Daniel J. Rubin, Saar Gill, Anthony R. Mato, Donald E. Tsai, Jessica K. Altman, Brenda K. Shelly, Alicia McLeish, Kyle W. Robinson, Donna Capozzi, Mitchell E. Hughes, Tanya Latorre, Allison Rago, Jennifer Gill, Daniel J. Landsburg, and James N. Gerson
Subjects: medicine.medical_specialty, business.industry, Venetoclax, Immunology, Follicular lymphoma, Salvage therapy, Retrospective cohort study, Cell Biology, Hematology, medicine.disease, Biochemistry, Clinical trial, Regimen, chemistry.chemical_compound, chemistry, Internal medicine, Ven, Medicine, Mantle cell lymphoma, business, health care economics and organizations
Abstract: Introduction: Venetoclax (VEN) is a highly effective agent for chronic lymphocytic leukemia (CLL) that targets BCL-2. Thus, it has been hypothesized to have efficacy in NHL and tested in phase-1/2 studies (Gerecitano JF, Blood 2015; de Vos S, Blood 2015; Davids MS, J Clin Oncol 2017). Overall response rates (ORR) observed in r/r NHL were 44% for all subtypes combined, 38% for follicular lymphoma (FL), 75% for mantle cell lymphoma (MCL), and 18% for diffuse large B-cell lymphoma (DLBCL). The adverse effect profile was consistent with the labeling despite dose escalation to doses higher than used in CLL. Additionally, VEN is a potential option in the r/r NHL setting, potentially providing less T cell toxicity compared to other agents used as bridging to T-cell therapies (Cummins NW, mBio, 2016; Dzhagalov I, J Immunol, 2008). We performed an analysis of all NHL patients (pts) treated with VEN at our institution to assess efficacy and safety of VEN in r/r NHL. Patients and Methods: We conducted a retrospective cohort study of all adult pts who received VEN for r/r NHL at the University of Pennsylvania between 4/2016 and 6/2018. Demographics, tumor lysis syndrome (TLS; events, prophylaxis and management), duration of therapy, reason for discontinuation, overall response, survival, and toxicities were examined. The primary endpoints were progression-free survival (PFS; defined as time from VEN start to disease progression or regimen change, death due to NHL or last-follow-up in remission), and overall survival using the Kaplan-Meier method. All other analyses were descriptive. Results: We identified 23 NHL pts for this analysis. NHL subtypes included DLBCL (35%; n=8), MCL (30%; n=7), Richter transformation (RT) (9%; n=2), transformed FL (tFL) (12%; n=4), post-transplant lymphoproliferative disease (PTLD) (4%; n=1), and marginal zone lymphoma (MZL; n=1) (4%). Median age at VEN start was 65 years; most pts were Ann Arbor stage IV (87%) and ECOG performance 2-4 (57%). NHL characteristics were MYC rearrangement (35%), BCL2 rearrangement (22%), double-hit lymphoma (26%), BCL2 IHC+ (22%), non-germinal center phenotype (13%). Median number of prior therapies was 4 (range: 2-13) with 17% having a prior autologous stem cell transplant. Median time to VEN initiation from prior therapy was 1 month (range, 0.5-9). Median VEN dose achieved was 400 mg (Range, 100-1200). Data for TLS are in Table 1. Median time on VEN was 2 months. While on VEN, 17% received radiation and 43% were on other anti-neoplastic therapy. Overall response rate (ORR) for the entire cohort was 26% (100% Partial Response [PR]). Subtypes with PR included MCL (13%), DLBCL (9%), and RT (4%). No PRs were observed with tFL, PTLD, nor MZL. Pts most commonly discontinued VEN for disease progression (74%); 2 pts (9%) remain on VEN therapy (range: 2-11 months). Median PFS and OS for the entire cohort were 2 months and 3 months, respectively, (Figure 1). Analyzed as histologic cohorts, large B-cell lymphomas (DLBCL, RT, PTLD, tFL) had similar median PFS and OS. However, small B-cell lymphomas (MCL, MZL) had median PFS and OS of 2.5 and 4 months, respectively. Two pts subsequently received CAR T-cell therapy post-VEN; one collected T-cells during VEN therapy and one collected T-cells prior to VEN start. Adverse events (AEs) occurred in approximately 65% while on VEN. AEs included: neutropenia (48%), thrombocytopenia (43%), TLS (30%), infection (26%), neutropenic fever (26%), and diarrhea (22%). One pt had an opportunistic infection (Pneumocystis jiroveci pneumonia) while on VEN and concurrent high-dose steroids. Conclusion: VEN monotherapy appears effective for NHL in phase I clinical trials. We describe our experience outside the setting of a clinical trial, including VEN used as part of multi-agent salvage therapy. Median PFS for our entire cohort is 2 months; AEs, while expected, were observed frequently, reflecting comorbidities. Clinical TLS events are attributed to pre-existing renal dysfunction (61% below 80 mL/min) during VEN escalation. The wide heterogeneity of VEN dose escalation, multi-agent combinations, and timing of initiation of VEN therapy are factors that require further investigation best designed as prospective clinical trials using other agents in combination with VEN. Disclosures Landsburg: Takeda: Consultancy; Curis: Consultancy, Research Funding. Schuster:Genentech: Honoraria, Research Funding; Novartis Pharmaceuticals Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Nordic Nanovector: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Consultancy, Honoraria, Research Funding; OncLive: Honoraria; Gilead: Membership on an entity's Board of Directors or advisory committees; Dava Oncology: Consultancy, Honoraria; Pfizer: Membership on an entity's Board of Directors or advisory committees; Physician's Education Source, LLC: Honoraria. Svoboda:Pharmacyclics: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; TG Therapeutics: Research Funding; Seattle Genetics: Consultancy, Research Funding; Regeneron: Research Funding; KITE: Consultancy; Kyowa: Consultancy; Merck: Research Funding. Gill:Novartis: Research Funding; Extellia: Consultancy, Membership on an entity's Board of Directors or advisory committees; Carisma Therapeutics: Equity Ownership. Mato:TG Therapeutics: Consultancy, Research Funding; AstraZeneca: Consultancy; Portola: Research Funding; Johnson & Johnson: Consultancy; Regeneron: Research Funding; Acerta: Research Funding; Celgene: Consultancy; Prime Oncology: Honoraria; Pharmacyclics, an AbbVie Company: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; Medscape: Honoraria. Altman:Epizyme: Other: payment to the institution to conduct clinical trial work; Incyte: Other: payment to the institution to conduct clinical trial work; Agios: Other: Payment to the institution to conduct the trial ; Pfizer: Other: payment to the institution to conduct clinical trial work; Ariad: Other: payment to the institution to conduct clinical trial work; BMS: Membership on an entity's Board of Directors or advisory committees; Astellas Pharma: Other; GSK: Other: payment to the institution to conduct clinical trial work; Boeringer Ingelheim: Other: payment to the institution to conduct clinical trial work; FujiFilm: Other: payment to the institution to conduct clinical trial work; Celgene: Membership on an entity's Board of Directors or advisory committees, Other: payment to the institution to conduct clinical trial work; Bayer: Other: payment to the institution to conduct clinical trial work; Celator: Other: payment to the institution to conduct clinical trial work; Cyclacel: Other: payment to the institution to conduct clinical trial work; Syros: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Genetech: Other: Payment to the institution to conduct clinical trial work; Janssen Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Immune Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees. Dwivedy Nasta:Pharmacyclics: Research Funding; Incyte: Research Funding; Roche: Research Funding; Aileron: Research Funding; Rafael/WF: Research Funding; Debiopharm: Research Funding; Merck: Other: DSMC; Takeda/Millenium: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees.
Published: 2018

8. Coronary computerized tomography angiography for rapid discharge of low-risk patients with cocaine-associated chest pain

Author: Jeanmarie Perrone, Christine M. McCusker, Kristy M. Walsh, Anna Marie Chang, Frances S. Shofer, Mark J. Collin, Judd E. Hollander, and Harold Litt
Subjects: medicine.medical_specialty, Acute coronary syndrome, Time Factors, Health, Toxicology and Mutagenesis, Myocardial Infarction, Coronary Vasospasm, Constriction, Pathologic, Coronary Artery Disease, Coronary Angiography, Toxicology, Chest pain, Risk Assessment, Severity of Illness Index, Angina Pectoris, Diagnosis, Differential, Coronary artery disease, Cocaine-Related Disorders, Predictive Value of Tests, Internal medicine, medicine, Humans, cardiovascular diseases, Myocardial infarction, Acute Coronary Syndrome, Prospective cohort study, medicine.diagnostic_test, business.industry, medicine.disease, Patient Discharge, Coronary vasospasm, Toxicology Investigations, Practice Guidelines as Topic, Angiography, Cardiology, Radiology, medicine.symptom, Emergency Service, Hospital, Tomography, X-Ray Computed, business, Electrocardiography
Abstract: Background Most patients presenting to emergency departments (EDs) with cocaine-associated chest pain are admitted for at least 12 hours and receive a “rule out acute coronary syndrome” protocol, often with noninvasive testing prior to discharge. In patients without cocaine use, coronary computerized tomography angiography (CTA) has been shown to be useful for identifying a group of patients at low risk for cardiac events who can be safely discharged. It is unclear whether a coronary CTA strategy would be efficacious in cocaine-associated chest pain, as coronary vasospasm may account for some of the ischemia. We studied whether a negative coronary CTA in patients with cocaine-associated chest pain could identify a subset safe for discharge.
Published: 2009

9. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis

Author: Elise A. Chong, Anthony R. Mato, Allison Rago, Tatyana Feldman, Kristy M. Walsh, Sunita D. Nasta, Jakub Svoboda, Christina Howlett, Stephen J. Schuster, Daniel J. Landsburg, Sonya J. Snedecor, Andre Goy, and Scott Weber
Subjects: Oncology, medicine.medical_specialty, Vincristine, Cyclophosphamide, Pharmacology, Disease-Free Survival, Proto-Oncogene Proteins c-myc, immune system diseases, Prednisone, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Progression-free survival, Etoposide, Ifosfamide, business.industry, Hematology, DNA-Binding Proteins, Survival Rate, Proto-Oncogene Proteins c-bcl-2, Cytarabine, Proto-Oncogene Proteins c-bcl-6, Rituximab, Lymphoma, Large B-Cell, Diffuse, business, medicine.drug
Abstract: Summary ‘Double-hit lymphomas’ (DHL), defined by concurrent MYC and BCL2 (or, alternatively, BCL6) rearrangements, have a very poor outcome compared to standard-risk, diffuse large B-cell lymphomas (DLBCL). Consequently, dose-intensive (DI) therapies and/or consolidation with high-dose therapy and transplant have been explored in DHL, although benefit has been debated. This meta-analysis compared survival outcomes in DHL patients receiving dose-escalated regimens [DI: R-Hyper-CVAD (rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone) or R-CODOX-M/IVAC (rituximab, cyclophosphamide, doxorubicin, vincristine, methotrexate/ifosfamide, etoposide, high dose cytarabine); or intermediate-dose: R-EPOCH (rituximab, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone)] versus standard-dose regimens (R-CHOP; rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in the first-line setting. Data were synthesized to estimate hazard ratios of dose-escalated treatments versus R-CHOP using a Weibull proportional hazards model within a Bayesian meta-analysis framework. Eleven studies examining 394 patients were included. Patients were treated with either front-line R-CHOP (n = 180), R-EPOCH (n = 91), or R-Hyper-CVAD/rituximab, methotrexate, cytarabine (R-M/C), R-CODOX-M/R-IVAC (DI) (n = 123). Our meta-analysis revealed that median progression-free survival (n = 350) for the R-CHOP, R-EPOCH and DI groups was 12·1, 22·2, and 18·9 months, respectively. First-line treatment with R-EPOCH significantly reduced the risk of a progression compared with R-CHOP (relative risk reduction of 34%; P = 0·032); however, overall survival (n = 374) was not significantly different across treatment approaches. A subset of patients might benefit from intensive induction with/without transplant. Further investigation into the role of transplant and novel therapy combinations is necessary.
Published: 2015

10. KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy

Author: Michael S. Weiss, Hari P. Miskin, Tracey Zimmer, John M. Pagel, Kristy M. Walsh, Paul M. Barr, Jeffrey J. Pu, Anthony R. Mato, Frederick Lansigan, Nicole Lamanna, Marshall T. Schreeder, Danielle M. Brander, Colleen Dorsey, Eline Luning-Prak, Dana Paskalis, Molly Fanning, Stephen J. Schuster, E. Paul Wileyto, Bruce D. Cheson, and Peter Sportelli
Subjects: Oncology, Cancer Research, medicine.medical_specialty, biology, business.industry, Kinase, Chronic lymphocytic leukemia, Phases of clinical research, medicine.disease, Discontinuation, chemistry.chemical_compound, chemistry, Ibrutinib, Internal medicine, medicine, biology.protein, Bruton's tyrosine kinase, business, PI3K/AKT/mTOR pathway
Abstract: TPS7569 Background: Although kinase inhibitor (KI) therapies, such as ibrutinib, are generally well tolerated, intolerance is the most common reason for discontinuation (d/c) in practice (~50%, Mato et al, Blood 2016). Additionally KI interruptions (≥ 8 days) can shorten OS (Barr et al, ASCO 2015). Fortunately, data suggest that KIs have non-overlapping toxicity profiles. Therefore, pts who d/c KI due to intolerance, with ongoing CLL response, represent an unmet need. TGR-1202 is a next generation, highly-specific PI3K-delta inhibitor with nanomolar inhibitory potency. TGR-1202 is well-tolerated with a d/c rate due to AEs of 8% as demonstrated in an integrated safety analysis of 165 treated pts (Burris et al, ASCO 2016). Methods: A phase 2 investigator initiated study is being conducted to assess the safety and activity of TGR-1202 in CLL pts who are KI intolerant. KI Intolerance is defined as ≥ 1 Gr 3 or ≥ 2 Gr 2 non-heme toxicities, ≥ 1 Gr 3 neutropenia with infection or fever, and/or ≥ 1 Gr 4 heme toxicity leading to KI (BTK and/or PI3K inhibitor) d/c (Table). Toxicities must resolve to ≤ Gr 1 prior to TGR-1202 dosing. Prior KI must be d/c for ≥ 14 days without progression (PD). All eligible pts are treated with TGR-1202 (800mg oral daily) until PD, toxicity or study conclusion. Primary study endpoint is PFS. Secondary endpoints include ORR, duration of response, time to treatment failure and TGR-1202 safety profile. Peripheral blood samples are collected prior to TGR-1202, after 28 days and at PD for correlative analyses to identify markers associated with KI intolerance. The trial commenced 10/1/2016. 55 eligible pts will be enrolled in approximately 12 months with 24 months follow-up. As of 1/2017, 10 study sites are enrolling pts with 10 more to be activated. To date, 10 pts have been enrolled and treated with TGR-1202. Clinical trial information: NCT02742090. [Table: see text]
Published: 2017

11. Relationship between renal dysfunction and outcomes in emergency department patients with potential acute coronary syndromes

Author: Meredith Edwards, Judd E. Hollander, Asako C. Matsuura, Emily Barrows, Kristy M. Walsh, Anna Marie Chang, and Jeffrey Le
Subjects: Adult, Male, Acute coronary syndrome, medicine.medical_specialty, Multivariate analysis, Myocardial Infarction, Critical Care and Intensive Care Medicine, Cohort Studies, chemistry.chemical_compound, Risk Factors, Internal medicine, medicine, Humans, cardiovascular diseases, Myocardial infarction, Acute Coronary Syndrome, Intensive care medicine, Aged, Creatinine, business.industry, Incidence (epidemiology), Incidence, General Medicine, Emergency department, Middle Aged, medicine.disease, Elevated creatinine, chemistry, Cardiovascular Diseases, Multivariate Analysis, Emergency Medicine, Female, Kidney Diseases, business, Emergency Service, Hospital, Biomarkers, Cohort study
Abstract: Objectives To determine whether patients with elevated creatinine who present to the emergency department (ED) with potential acute coronary syndrome (ACS) are at an increased risk of acute myocardial infarction (AMI) or 30-day cardiovascular (CV) events. Methods A secondary analysis of a cohort study of patients presenting to the ED with potential ACS with serum creatinine measurements. Research assistants collected demographics, history, symptoms, hospital course and 30-day follow-up. Outcomes measured were in-hospital AMI and 30-day CV events (death, nonfatal AMI, revascularisation). Prespecified multivariable models included age, gender, race and cardiac risk factors and presenting electrocardiogram (ECG). We used a creatinine cut-off point of 132.6 mmol/l. Data are presented as OR and 95% CI. Results 3451 patients were enrolled (age, 52.9±13.2; 55% female patients; 64% black patients). There were 120 AMI during initial visit and 232 patients had 30-day CV events (43 deaths, 128 AMI, 120 revascularisations). Creatinine values were normal in 3086 (89.4%) and abnormal in 365 (10.5%) patients. In multivariable models the adjusted OR (95% CI) for the association between abnormal creatinine and AMI was 1.43 (0.88 to 2.30) and 30-day CV events was 1.57 (1.10 to 2.25). The odds of 30-day CV events were increased for patients who were older, male subjects, white, had hyperlipidaemia, hypertension or a history of CAD, or presented with an abnormal ECG. Conclusion In patients with potential ACS in the ED, renal dysfunction predicts a higher likelihood of 30-day CV events, but not an independent predictor after controlling for other risk factors. It appears to be a marker of other CV risks.
Published: 2012

12. Deep Sedation

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

13. Hyperbarics

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

14. Heart–Kidney Interaction

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

15. Hemodynamic monitoring

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

16. Hollow Fiber Membranes

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

17. High-Frequency Ventilation

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

18. Decompression Sickness

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

19. HIV-Related Gastrointestinal Obstruction

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

20. HIV, Pneumonic Complications

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

21. Dialysis Membranes

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

22. Delayed Thoracotomy

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

23. Diffuse Alveolar Damage

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

24. Domestic Violence

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

25. 2,6-Diisopropylphenol

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

26. High-Frequency Oscillatory Ventilation (HFOV)

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

27. Humidification

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

28. Hepatic Trisegmentectomy

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

29. Herpes Simplex

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

30. Herpes Zoster

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

31. Diabetes, Others (Acute Conditions/Emergencies)

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

32. HIV, Hematogenous Tuberculosis

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

33. Hemoperfusion

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

34. Dyspnea: Differential Diagnosis

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

35. Death by Neurologic Criteria

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

36. Dressing

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

37. Hemorrhagic Fever Virus

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

38. Hepatotomy

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

39. Dermatome

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

40. Hyperinsulinemic Euglycemia Therapy (HIET)

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

41. Damage Control

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

42. Discontinuation

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

43. Disaster Management

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

44. Deerfly Fever

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

45. Hypoxic Hypoxia

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

46. Desmopressin: DDAVP, 1-Desamino-Cys-8-d-Arginine-Vasopressin

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

47. Diagnostic Peritoneal Lavage

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

48. Hypothalamic-Pituary-Adrenal (HPA) Disorder

Author: Jeffrey N. Harr, Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan, Alan S. Maisel, Derek S. Wheeler, Hector R. Wong, Mark A. Malangoni, Gili Kenet, Gideon Paret, Tiffany Tello, Jason M. Phillips, Fernando J. Kim, Christophe Vinsonneau, John R. Prowle, Rinaldo Bellomo, Sacha Zeerleder, Mini Michael, Frederick A. Moore, Hunter B. Moore, Ernest E. Moore, Andrew Davenport, J. P. J. Wester, Carlton C. Barnett, Sarah E. Judkins, Constantine Karvellas, Mustafa Hussain, H. Leon Pachter, Catharina F. M. Linssen, Natalia Mendoza, Blanca Ochoa, Katie Morrison, Beau Willison, Stephen K. Tyring, Kristy M. Walsh, Catherine T. Shoff, Suzanne M. Shepherd, William H. Shoff, Othman Solaiman, Niall D. Ferguson, Christopher H. Mody, Alison Morris, Laurence Huang, Philip LoBue, James Riddell, Julius Larioza, Daniel J. Skiest, Davide Chiumello, Antonella Marino, Kai Singbartl, Alexander Zarbock, Caesar A. Anderson, Brigitte M. Baumann, Itoro Elijah, Jong O. Lee, David N. Herndon, and Laura J. Porro
Published: 2012

49. Dengue Vasculopathy

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

50. Decreased Kidney Function

Author: Hesham M. Ahmed, Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli, Lucido L. Ponce, Claudia S. Robertson, Luke Macyszyn, M. Sean Grady, Aneet Deo, Andrew S. Levey, Charles D. Deakin, Suzanne M. Shepherd, William H. Shoff, Philip F. Stahel, Michael A. Flierl, Elena Volpi, Maria L. Belalcazar, Gabriel A. Mecott, Marc G. Jeschke, N. I. Abate, M. Chandalia, Erwin R. Thal, R. T. Noel Gibney, Zhongping Huang, William R. Clark, Claudio Ronco, Michelle A. Fischer, Jeffry L. Kashuk, Marcel M. Levi, Melissa A. Miller, Pascal Vranckx, Bart De Moor, Barbara De Meuter, Adam Romanovsky, Sean M. Bagshaw, Kristy M. Walsh, David Lambert, Mitchell C. Sokolosky, Anan Chuasuwan, John A. Kellum, Sonia Labeau, Dominique Vandijck, Stijn Blot, Neesh Pannu, J. Matthew Fields, Anthony J. Dean, Alan S. Maisel, Wahida Sekandar, and Leo Slavin
Published: 2012

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

220 results on '"Kristy M. Walsh"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources